Results 261 to 270 of about 704,542 (298)

Early benefit assessment of new drugs in Germany – Results from 2011 to 2012

Health Policy, 2014
Rising drug costs in Germany led to the Act on the Reform of the Market for Medicinal Products (AMNOG) in January 2011. For new drugs, pharmaceutical companies have to submit dossiers containing all available evidence to demonstrate an added benefit versus an appropriate comparator therapy.
Natalie Mcgauran, Beate Wieseler
exaly   +3 more sources

Benefit Finding and Related Factors of Patients with Early-Stage Cancer in China [PDF]

International Journal of Environmental Research and Public Health, 2022
(1) Background: Although the research on benefit finding (BF) in China has increased in recent years, it remains in its infancy. Few previous studies have focused on early-stage cancer patients.
Xichenhui Qiu, Liyuan Sun
exaly   +2 more sources

Early assessment of ESD benefit

International Shipbuilding Progress, 2017
One of the first stages during the evaluation of the viability of an Energy Saving Devices (ESDs) for existing ships is a global scan of the field of application, performance and the required investment. Based on this preliminary data the Return on Investment (RoI) for an ESD retrofit can be estimated, which is a key figure in decision making processes.
Voermans, A.A.M., Cales, T.A.J.
openaire   +1 more source

Methods for Early Control of Abdominal Hemorrhage: An Assessment of Potential Benefit

Journal of Special Operations Medicine, 2018
Noncompressible truncal hemorrhage (NCTH) after injury is associated with a mortality increase that is unchanged during the past 20 years. Current treatment consists of rapid transport and emergent intervention. Three early hemorrhage control interventions that may improve survival are placement of a resuscitative endovascular balloon occlusion of the ...
Paul M, Cantle, Matthew J, Hurley, Michael D, Swartz, John B, Holcomb   +3 more
openaire   +2 more sources

[Challenges of Determining the Prevalence and Incidence of Urothelial Carcinoma in Early Benefit Assessment].

Gesundheitswesen (Bundesverband der Arzte des Offentlichen Gesundheitsdienstes (Germany)), 2021
Since the introduction of the Medicines Market Reorganization Act (AMNOG) in 2011, there have been some structural changes for pharmaceutical manufacturers, due to the early assessment of benefits in the market launch of innovative drugs. This means that the manufacturer is constantly faced with challenges in determining the target population by using ...
Joelin, Wortmann, Daniel, Wirth
openaire   +2 more sources

Early Benefit Assessment of Pharmaceuticals in Germany

Medical Decision Making, 2014
Background. Since 2011, when the German Pharmaceutical Market Restructuring Act (AMNOG) came into effect, newly licensed pharmaceuticals must demonstrate an added benefit over a comparator treatment to be reimbursed at a value greater than the reference price.
Fischer, Katharina E., Stargardt, Tom
openaire   +2 more sources

A decade of early benefit assessment of ophthalmic drugs in Germany: success story or not?

Expert Review of Pharmacoeconomics & Outcomes Research, 2021
To analyze how ophthalmic drugs fared in the early benefit assessment (EBA) after its introduction in Germany up to 2020 and to quantify its impact on their negotiated prices.Relevant documents were screened and essential content on added benefit outcomes and the underlying evidence was extracted next to pricing information.
openaire   +2 more sources

Benefits of transvaginal sonographic assessment of early pregnancy

2001
Objective: The aim of this study was to investigate the benefits of transvaginal sonographic assessment of early pregnancy. Material and Methods: As a prospective observational study, 103 pregnant women were follovved until delivery or completion of a failed pregnancy.
Madazlı, Rıza, TUNALI, Süheyl, İDİL, Mehmet, AKSU, Feridun   +3 more
openaire   +3 more sources

Early benefit assessment for pharmaceuticals in Germany: lessons for policymakers.

Issue brief (Commonwealth Fund), 2013
Since 2011, Germany's Pharmaceutical Market Restructuring Act has mandated that all newly introduced drugs are subject to an assessment of their benefits in relation to a comparator, typically the current standard treatment. For drugs found to have some additional benefit, the manufacturer and the statutory health insurers negotiate a price.
Sophia, Schlette, Rainer, Hess
openaire   +1 more source

[Subgroups in the early benefit assessment of pharmaceuticals: a methodical review].

Zeitschrift fur Evidenz, Fortbildung und Qualitat im Gesundheitswesen, 2016
Benefit assessments according to Sect. 35a of the Social Code Book V are frequently divided into subsets of populations. This division of therapeutic indications is evident in almost every other of the completed appraisals by the Federal Joint Committee (G-BA).
Andrej, Rasch, Charalabos-Markos, Dintsios   +1 more
openaire   +1 more source